The company also today announced that Jeryl (“Jeri”) Hilleman, Chief Financial Officer, will step down as part of a planned transition at the beginning of 2020 so that she can focus on board responsibilities. The Board has initiated a search process to identify Intersect ENT’s next CFO.
“We want to express our deep appreciation for Jeri’s many and significant accomplishments over the years, and are deeply grateful for her commitment to ensure a seamless transition throughout this planned process,” said Mr. Gallahue. “Jeri has contributed broadly to the organization over the years, and we wish her well in the next stage of her career.”
Ad Statistics
Times Displayed: 2548
Times Visited: 12 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
About Intersect ENT®
Intersect ENT is dedicated to transforming ear, nose and throat care by providing innovative, clinically meaningful therapies to physicians and patients. The company’s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care.
Intersect ENT is a registered trademark of Intersect ENT, Inc.
Back to HCB News
